Ir-med, INC 8-K filings

IR-Med, Inc. announced the closing of a private placement offering, issuing common stock and warrants to purchase additional shares, raising $19,054 in gross proceeds.

IR-Med, Inc. completed a private placement offering raising $43,619 and announced the immediate resignation of its CEO, Ran Ziskind, due to strategic disagreements.

IR-Med, Inc. announced financial difficulties, delaying its Q3 2025 10-Q filing and transitioning its CEO and CFO to hourly compensation.

IR-Med, Inc. completed a private placement offering, raising $25,000 through the sale of common stock and warrants, with significant participation from its CEO.

IR-MED, Inc. converted $155,437 of outstanding debt, including accrued interest, into 11,956,692 shares of common stock at $0.013 per share, primarily with company directors.

IR-Med, Inc. completed a private placement offering, raising $64,754 through the sale of common stock and warrants, with significant participation from company directors.

IR-Med, Inc. announced the termination of employment for Chief Development Officer Aharon Binur, effective August 31, 2025.

IR-Med, Inc. disclosed a second amendment to its Chief Financial Officer Sharon Levkoviz's employment agreement, drastically cutting his monthly salary to NIS 7,500 and reducing his work scope to 25%, effective August 1, 2025.

IR-Med, Inc. announced that Williamsburg Venture Holdings, LLC failed to remit a $500,000 payment for common stock as per their Equity Purchase Agreement, prompting the company to pursue legal enforcement.

IR-Med, Inc. announced the completion of a private placement offering that raised $88,678 by selling 591,187 shares of common stock at $0.15 per share, with the offering reportedly closing on June 9, 2024, nearly a year before the current 8-K filing date of June 5, 2025.

IR-Med, Inc. appoints Yechiel Even, a seasoned economic consultant and investment banker, as an independent director to its board, effective immediately.

IR-Med Inc. has secured an advance payment of $171,468 from the Israeli Innovation Authority (IIA) to support the development of a device for assessing diabetic foot ulcers.

IR-Med, Inc. has entered into a Note Purchase Agreement, raising $31,200 through the issuance of unsecured convertible promissory notes to three investors.

IR-Med, Inc. has entered into an Equity Purchase Agreement with Williamsburg Venture Holdings, LLC, securing a commitment for up to $15 million in investment over a 24-month period.

IR-Med, Inc. has terminated its distribution agreement with PI Prevention Care LLC due to the distributor's failure to pay the required license fee.

IR-Med, Inc. released an updated investor presentation on September 17, 2024, which was posted to its website.

IR-MED's PressureSafe device, designed for early detection of pressure injuries, has commenced a usability study at Methodist Healthcare in San Antonio, Texas.

IR-Med, Inc. has appointed Ran Ziskind, a seasoned tech entrepreneur, as its new Chief Executive Officer, effective September 1, 2024, to lead the company's growth phase.

IR-Med, Inc. has amended consulting agreements with its Interim CEO and Chief Scientific Officer, increasing their monthly compensation.

IR-Med Inc. has completed a private placement, issuing common stock and warrants to investors, raising $715,000.

IR-MED's PressureSafe device has received FDA listing as a decision support tool for pressure injuries, paving the way for its U.S. market launch.

IR-Med, Inc. has appointed its Chief Technology Officer and co-founder, Aharon Klein, as Interim Chief Executive Officer, effective February 28, 2024.

IR-Med, Inc. has terminated its CEO and reduced its workforce due to financial challenges, also limiting operations until sufficient funding is secured.

Inna Martin has resigned from the board of directors of IR-Med, Inc., effective immediately, with no indication of disagreement with the company's operations or policies.